Fungitraxx

Itraconazole, the active ingredient in Fungitraxx, is an azole antifungal presented as oral capsules for oral use. It is employed to treat a range of systemic mycoses such as aspergillosis, blastomycosis and histoplasmosis, as well as superficial infections like dermatophytosis and candidiasis, in both adult and pediatric patients under medical supervision.

GNH USA supplies Fungitraxx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate global distribution.

Itraconazole is used to manage fungal infections by inhibiting the ergosterol synthesis pathway essential for fungal cell membranes.

Aspergillosis: effective for invasive disease caused by Aspergillus species. Blastomycosis: clears systemic infection by Blastomyces dermatitidis. Histoplasmosis: treats disseminated Histoplasma capsulatum infection. Dermatophytosis and candidiasis: resolves superficial skin and mucosal fungal infections.

Common Side Effects: - Nausea or vomiting. - Abdominal discomfort or pain. - Headache. - Rash or pruritus. - Elevated liver enzymes. - Taste disturbances.

Serious or Rare Side Effects: - Hepatotoxicity, including severe liver injury. - Congestive heart failure or worsening of existing heart failure. - Severe skin reactions such as Stevens‑Johnson syndrome. - QT interval prolongation and cardiac arrhythmias. - Anaphylactic reactions. - Visual disturbances.

Before initiating therapy, consider the following precautions: - Liver function monitoring: obtain baseline liver tests and repeat periodically. - Drug interaction review: assess concomitant medications for CYP3A4 interactions. - Cardiac risk assessment: avoid in patients with existing heart failure. - Pregnancy and lactation: use only if potential benefit outweighs risk. - Renal impairment: evaluate need for dose adjustment in severe cases. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Itraconazole has a notable interaction profile that requires careful management.

Major Interactions (Avoid): - Rifampin, carbamazepine, phenytoin, or St. John's Wort: strong inducers that markedly reduce itraconazole exposure. - Ketoconazole: additive hepatotoxicity when combined.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors such as erythromycin, clarithromycin, or protease inhibitors: may increase itraconazole levels. - Statins (e.g., simvastatin): heightened risk of myopathy. - Warfarin: potential alteration of anticoagulant effect. - Digoxin: possible increase in serum concentrations. - Oral contraceptives: efficacy may be reduced.